日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

BMS-986365 (CC-94676) 是一种双重雄激素受体配体导向降解剂和拮抗剂,在既往接受过大量治疗的转移性去势抵抗性前列腺癌患者中的安全性和临床活性

Rathkopf, D E; Patel, M R; Choudhury, A D; Rasco, D; Lakhani, N; Hawley, J E; Srinivas, S; Aparicio, A; Narayan, V; Runcie, K D; Emamekhoo, H; Reichert, Z R; Nguyen, M H; Wells, A L; Kandimalla, R; Liu, C; Suryawanshi, S; Han, J; Wu, J; Arora, V K; Pourdehnad, M; Armstrong, A J

Fragmentomic analysis of circulating tumor DNA-targeted cancer panels

循环肿瘤DNA靶向癌症基因组片段组学分析

Helzer, K T; Sharifi, M N; Sperger, J M; Shi, Y; Annala, M; Bootsma, M L; Reese, S R; Taylor, A; Kaufmann, K R; Krause, H K; Schehr, J L; Sethakorn, N; Kosoff, D; Kyriakopoulos, C; Burkard, M E; Rydzewski, N R; Yu, M; Harari, P M; Bassetti, M; Blitzer, G; Floberg, J; Sjöström, M; Quigley, D A; Dehm, S M; Armstrong, A J; Beltran, H; McKay, R R; Feng, F Y; O'Regan, R; Wisinski, K B; Emamekhoo, H; Wyatt, A W; Lang, J M; Zhao, S G

Clinical trials for metastatic castrate-resistant prostate cancer-who is looking after the control patients? Questions for the future

转移性去势抵抗性前列腺癌的临床试验——谁来照顾对照组患者?未来需要探讨的问题

Ardolino, L C; Dear, R; Armstrong, A J; Gillessen, S; Joshua, A M

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

循环肿瘤细胞计数(Epic Sciences)作为转移性去势抵抗性前列腺癌男性患者预后生物标志物的开发和验证

Scher, H I; Armstrong, A J; Schonhoft, J D; Gill, A; Zhao, J L; Barnett, E; Carbone, E; Lu, J; Antonarakis, E S; Luo, J; Tagawa, S; Dos Anjos, C H; Yang, Q; George, D; Szmulewitz, R; Danila, D C; Wenstrup, R; Gonen, M; Halabi, S

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

前列腺癌疾病状态的命名及其临床实用性:玫瑰换个名字可能就不那么香了。

Armstrong, A J; Antonarakis, E S; Taplin, M-E; Kelly, W K; Beltran, H; Fizazi, K; Dahut, W L; Shore, N; Slovin, S; George, D; Carducci, M A; Corn, P; Danila, D; Dreicer, R; Heath, E; Rathkopf, D; Liu, G; Nanus, D; Stein, M; Smith, M R; Sternberg, C; Wilding, G; Nelson, P S; Halabi, S; Kantoff, P; Clarke, N W; Evans, C P; Heidenreich, A; Mottet, N; Gleave, M; Morris, M J; Scher, H I

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

建立和验证用于预测未接受化疗的转移性去势抵抗性前列腺癌患者总生存期的预后模型

Armstrong, A J; Lin, P; Higano, C S; Sternberg, C N; Sonpavde, G; Tombal, B; Templeton, A J; Fizazi, K; Phung, D; Wong, E K; Krivoshik, A; Beer, T M

Effect of Prophylactic Calcitriol Administration on Serum Ionized Calcium Concentrations after Parathyroidectomy: 78 Cases (2005-2015)

预防性应用骨化三醇对甲状旁腺切除术后血清离子钙浓度的影响:78 例(2005-2015 年)

Armstrong, A J; Hauptman, J G; Stanley, B J; Klocke, E; Burneko, M; Holt, D E; Runge, J J; Rubin, J A

Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting

雄激素受体变异驱动的前列腺癌:临床意义和治疗靶点

Antonarakis, E S; Armstrong, A J; Dehm, S M; Luo, J

Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer.

对局限性前列腺癌男性患者上皮可塑性生物标志物组合的评估

Armstrong A J, Healy P, Halabi S, Vollmer R, Lark A, Kemeny G, Ware K, Freedland S J

Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer

双硫仑治疗非转移性复发性前列腺癌男性患者的药效学研究

Schweizer, M T; Lin, J; Blackford, A; Bardia, A; King, S; Armstrong, A J; Rudek, M A; Yegnasubramanian, S; Carducci, M A